Cargando…
Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer
IMPORTANCE: Gastric cancer is the fifth most common cancer worldwide, and investigating its incidence, characteristics, treatment, and outcomes over the past decades can help in selecting clinical strategies and future research directions. OBJECTIVE: To analyze the trends in incidence, staging, and...
Autores principales: | van Velzen, Merel J. M., Braemer, Michelle, Nieuwenhuijzen, Grard A. P., van Sandick, Johanna W., Siersema, Peter D., Ruurda, Jelle P., Verheij, Marcel, Spaander, Manon C. W., Beerepoot, Laurens V., Haj Mohammad, Nadia, van Laarhoven, Hanneke W. M., Verhoeven, Rob H. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442714/ https://www.ncbi.nlm.nih.gov/pubmed/37603334 http://dx.doi.org/10.1001/jamanetworkopen.2023.30018 |
Ejemplares similares
-
A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022) -
Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
por: Kroese, Tiuri E., et al.
Publicado: (2022) -
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021) -
The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer
por: Doeve, Benthe H., et al.
Publicado: (2023) -
Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)